In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...
The court directed the firm to pay Ms Gichuki 10 months’ salary as compensation would be adequate in the circumstances ...
Phil Stevens, from Hampshire, said he developed an addiction to gambling and spending after taking prescription medication ...
Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
Manchester-based HIV charity George House Trust has won a GSK Impact Award – one of the nation’s top healthcare charity ...
11h
The Citizen on MSNAnalysis-As Trump thaws ties, Russia has a new public enemy number one: BritainAs the U.S. under Donald Trump seeks to reset ties with Moscow and broker peace between Russia and Ukraine, Britain has been ...
Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...
Annual ResultsBIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS 14.03.2025 / 07:00 CET/CESTBasel, Switzerland. March 14, 2025, 7am CETBioVersys AG (SIX: BIOV), ...
GlaxoSmithKline is investing in artificial ... clients in one quarter of the time normally needed. Exscientia and GSK aim to discover novel and selective small molecules for up to 10 disease ...
Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...
GlaxoSmithKline has agreed a $3.3 billion takeover ... that for years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for Cambridge, Massachusetts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results